Yi Lin, MD
Enriched profileProfessor of Medicine (joint appointment, Division of Hematology and Division of Experimental Pathology and Laboratory Medicine); Chair, Cellular Therapies and Gene and Viral Therapies Disease Team, Mayo Clinic Comprehensive Cancer Center · Mayo Clinic
Yi Lin is Professor of Medicine (joint appointment, Division of Hematology and Division of Experimental Pathology and Laboratory Medicine); Chair, Cellular Therapies and Gene and Viral Therapies Disease Team, Mayo Clinic Comprehensive Cancer Center at Mayo Clinic. OpenAlex indexes 995 publications with 40,137 citations (h-index 80); ClinicalTrials.gov lists 31 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Yi Lin, MD, is Professor of Medicine (joint appointment, Division of Hematology and Division of Experimental Pathology and Laboratory Medicine) at Mayo Clinic, Rochester, MN. The public record shows 995 publications with 40,137 citations (h-index 80), centered on CAR-T cell therapy research, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 31 registered clinical trials, industry payments reported by 19 companies, 5 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: CAR-T cell therapy research
- 31 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 69 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 324.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 31 registered studies on ClinicalTrials.gov. The most recent:
- Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for "My Health Bank" App Use Among Adults Over 50
Sponsor: Tri-Service General Hospital (TSGH)
- The Effects of Home-based Graded Repetitive Arm Supplementary Program Group on Stroke.
Sponsor: National Taiwan University Hospital
Industry payments
Updated 16 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202511 payments$25,874openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20255 payments$19,327openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year202511 payments$13,126openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
97.8%SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor97%Remdesivir100%Part B, office-administered≥12 patientsShort-acting sulfonamides0.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsCancer & immunology
1.5%Thalidomide Analog1.5%Revlimid58%Lenalidomide42%Part D≥12 patientsDermatology
0.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.7%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
5 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Define the mechanisms targeting a B. burgdorferi protein CspZ to prevent Lyme disease infection
Tufts University Boston
FY2026$862,348R01AI184476 - Immunomodulatory mechanisms of wild bird reservoir hosts that facilitate persistence of Lyme disease bacteria
Tufts University Boston
FY2026$838,799R01AI181746 - Neonatal Hypoxic Ischemic Encephalopathy: Potential of Innovative NIRS to Optimize Hypothermia
Boston Children'S Hospital
FY2026$758,929R01HD076258
Congress activity
Updated 16 Oct 2026
226 congress contributions (2013–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Administration of tarlatamab in an outpatient setting utilizing remote patient monitoring: Mayo Clinic experience.
ASCO Annual Meeting
ASCO2025Co-author - Association of immune cell subsets and cytokine profiles with immune-related hyperinflammatory states after CAR T-cell therapy.
ASCO Annual Meeting
ASCO2025Co-author - Comparisons of survival outcomes of antibody-drug-conjugates in metastatic breast cancer: A network meta-analysis.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.
Research square
Article2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Management of hematological toxicities after BCMA-directed CAR-T cell therapy.
Blood cancer journal
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- M.D.
Ph.D., Northwestern University Feinberg School of Medicine (McGaw Medical Center of Northwestern University)
2004provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board certification: American Board of Internal Medicine
Internal Medicine, Hematology, and Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Chair
Cellular Therapies and Gene and Viral Therapies Disease Team, Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
Secondary affiliations
appointments beyond the home institution- Enterprise leader
Cancer Regenerative Medicine, Biotherapeutics and Biomanufacturing, Mayo Clinic
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Co-chair
Experimental and Novel Therapeutics Disease Group, Mayo Clinic Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →alumniassociation.mayo.edu ↗
Media & interviews
press, podcasts and appearances- Mayo Clinic Q&A podcast
discussed immunotherapy advances in treating multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsnetwork.mayoclinic.org ↗ - Mayo Clinic Radio (Sept 22 broadcast)
explained CAR T-cell therapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.mayocliniclabs.com ↗ - VJHemOnc video interview series
cellular therapy, immunotherapy and cancer vaccination in lymphoma and myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - OncLive video interview
CAR T-cell therapy-related toxicities in multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens